Notice of Head Office Relocation

OSAKA, Japan, July 11, 2024 - Shionogi & Co., Ltd.  (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereinafter "Shionogi") announced that it will relocate its current head office to Grand Green Osaka, part of the Umekita Phase 2 Development Project in Kita-ku, Osaka, after the summer of 2025.

1.    Overview of the relocation

・  New address
24th to 26th floors of Grand Green Osaka Park Tower, 5-54 Ofukacho, Kita-ku, Osaka 530-0011

・  Relocation period
After summer 2025

・  An affiliated company that will also be relocating at the same time
Shionogi Healthcare Co., Ltd. (Head office: Chuo-ku, Osaka City; Corporate Officer, President: Satoru Yoshimoto)

2.    Background and purpose of the relocation

Shionogi has been operating its business from its headquarters in Doshomachi, Osaka since it was founded as a drug wholesaler, Shiono Gisaburo Shoten, in 1878. Starting in 2020, Shionogi has set a goal of evolving into an HaaS (Healthcare as a Service) company that can provide healthcare solutions, centered on drug discovery, globally as part of its medium-term management strategy, SHIONOGI Transformation Strategy 2030 (STS2030). In the process, the company has decided to relocate its headquarters in order to review its global headquarters functions, and build a system for more efficient and effective management.

We believe that the concept of Grand Green Osaka, our new location, will accelerate the realization of our vision.

3.    New office features

・  The Office as the “FACE” of the Global Headquarters

We define the role of our new headquarters as a space where proud and ambitious employees come together to create new value and support the ever-evolving SHIONOGI. The office concept designed to fulfill this role is entitled “FACE.” The FACE concept embodies the meanings of “energizing face-to-face communication,” “confronting challenges,” and “delivering smiles, becoming a place of joy.” As the hub for communication within the global SHIONOGI family and a welcoming environment for diverse business partners, we aim to establish an office and headquarters functions that befit our status as a global base.

・  An Office Environment That Fosters Innovation

With an eye toward strengthening collaboration with government, academia, startups, and ventures, we will establish a new base for open innovation that promotes co-creation and cooperation with various business partners. Furthermore, while respecting diverse working styles within the company, we aim to create an environment where enhanced communication and collaboration among employees lead to further improvements in the quality and speed of business activities, fostering the creation of new value.

・  Further Enhancement of Safety and Security

As a healthcare provider, SHIONOGI bears the social responsibility to consistently supply products and services that contribute to the treatment of diseases and improvement of the quality of life. At our relocated headquarters office, we anticipate not only creating a safer and more secure workplace for our employees, but also enhancing our adaptive capacity to maintain physical and functional headquarters functions in unforeseen circumstances.

・  Establishing a More Advanced Security Environment

As the core function of a pharmaceutical company handling information assets, we will construct a higher security environment. Recognizing information leakage as a critical risk for the company, we aim to create an environment where strict management of information maintains our competitive edge.

4.    Utilizing the current head office

The current head office will continue to be utilized as an important base for SHIONOGI, taking into consideration its historical background as the site where SHIONOGI was founded. Currently, Shionogi Pharma Co., Ltd., which is responsible for the manufacturing division of the SHIONOGI Group, and other group companies will use the site.

Although relocating our headquarters from the place where we were founded is a major decision, we believe that this is a necessary step for SHIONOGI to continue to grow as a company that "provides the best medicines (healthcare solutions)" globally, by our 150th anniversary in 2028 and into the future beyond. We will continue to strive to contribute to society by creating, manufacturing, and selling even better medicines.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html